Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

Overview of attention for article published in BMC Cancer, August 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (59th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 1,837 followers.

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. https://t.co/4e16YVkc2I https://t.co/hGD99Uyy5N

07 Aug 2022

Reply Repost Favourite

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial https://t.co/huTUhLbOxf https://t.co/2RdpMqSgkY

05 Aug 2022

Reply Repost Favourite

New article: Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial https://t.co/cJLn9lYMwD #melanoma #oncology https://t.co/rAPGt0V8Eg

05 Aug 2022

Reply Repost Favourite

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial https://t.co/jvrjUpMBY1

05 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.